Circulating myeloid-derived suppressor cells predict differentiated thyroid cancer diagnosis and extent

Thyroid

Volumn 26, Issue 3, 2016, Pages 381-389

  Angell, Trevor E ^a   Lechner, Melissa G ^a   Smith, Alison M ^b   Martin, Sue E ^b   Groshen, Susan G ^b   Maceri, Dennis R ^b   Singer, Peter A ^b   Epstein, Alan L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; HLA DR ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUMOR MARKER;

ADULT; ARTICLE; CANCER CYTODIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIATED THYROID CANCER; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; MYELOID DERIVED SUPPRESSOR CELL; OBSERVATIONAL STUDY; PILOT STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; SUPPRESSOR CELL; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROIDECTOMY; AGED; BLOOD; CELL DIFFERENTIATION; IMMUNOLOGY; IMMUNOPHENOTYPING; MYELOID-DERIVED SUPPRESSOR CELL; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; BIOMARKERS, TUMOR; BIOPSY, FINE-NEEDLE; CELL DIFFERENTIATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHENOTYPE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; THYROID NEOPLASMS; THYROID NODULE; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84962544866     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2015.0289     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics, 2012. CA Cancer J Clin 62: 10-29
2. Popoveniuc G, Jonklaas J. (2012). Thyroid nodules. Med Clin North Am 96: 329-349
3. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. (2009). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167-1214
4. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, Vitti P; AACE/AME/ETA Task Force on Thyroid Nodules. (2010). American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J Endocrinol Invest 33: 51-56
5. Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD Jr, Kim BW, Nosé V, Marqusee E, Larsen PR, Alexander EK. (2007). Long-Term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 111: 508-516
6. Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. (2001). Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery 130: 921-930
7. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Hölzer S. (2000). Initial results from a prospective cohort study of. (5583). cases of thyroid carcinoma treated in the United States during 1996: an American College of Surgeons Commission on Cancer Patient Care Evaluation Study. Cancer 89: 202-217
8. Cibas ES, Ali SZ. (2009). The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 19: 1159-1165
9. Bernet V, Hupart KH, Parangi S, Woeber KA. (2014). AACE/ACE Disease State Commentary: molecular diagnostic testing of thyroid nodules with indeterminate cytopathology. Endocr Pract 20: 360-363
10. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN. (2009). Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94: 2092-2098
11. Kim MI, Alexander EK. (2012). Diagnostic use of molecular markers in the evaluation of thyroid nodules. Endocr Pract 18: 796-802
12. Angell TE, Alexander EK. (2014). Validation and multicenter clinical experience of the Afirma- Gene Expression Classifier. US Endocrinol 10: 117-119
13. Davies L, Welch HG. (2006). Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167
14. Chen AY, Jemal A, Ward EM. (2009). Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115: 3801-3807
15. Harach HR, Franssila KO, Wasenius VM. (1985). Occult papillary carcinoma of the thyroid. A 'normal' finding in Finland. A systematic autopsy study. Cancer 56: 531-538
16. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, Miyauchi A. (2003). An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13: 381-387
17. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M. (2006). Long-Term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892-2899
18. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674
19. Stewart TJ, Abrams SI. (2008). How tumours escape mass destruction. Oncogene 27: 5894-5903
20. Diaz-Montero CM, Finke J, Montero AJ. (2014). Myeloidderived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 41: 174-184
21. Stewart TJ, Smyth MJ. (2011). Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metast Rev 30: 125-140
22. Serafini P. (2013). Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol Res 57: 172-184
23. Bak SP, Alonso A, Turk MJ, Berwin B. (2008). Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol 46: 258-268
24. Nagaraj S, Gabrilovich DI. (2008). Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68: 2561-2563
25. Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE. (2009). Mammary tumor heterogeneity in the expansion of myeloidderived suppressor cells. Int Immunopharmacol 9: 937-948
26. Gabrilovich DI, Nagaraj S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174
27. echner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, Epstein AL. (2011). Functional characterization of human CD33+ and CD11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 9: 90
28. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. (2014). Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 1319: 47-65
29. Khaled YS, Ammori BJ, Elkord E. (2013). Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol 91: 493-502
30. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. (2009). Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol Immunother 58: 49-59
31. American Joint Committee on Cancer. (2009). American Joint Committee on Cancer Staging Manual. Seventh edition. Springer-Verlag, New York
32. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. (2012). Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 381: 14-22
33. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. (1993). Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of. (1779). patients surgically treated at one institution during. (1940). through 1989. Surgery 114: 1050-1057
34. Cibas ES, Baloch ZW, Fellegara G, LiVolsi VA, Raab SS, Rosai J, Diggans J, Friedman L, Kennedy GC, Kloos RT, Lanman RB, Mandel SJ, Sindy N, Steward DL, Zeiger MA, Haugen BR, Alexander EK 2013A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med 159: 325-332
35. Beaudenon-Huibregtse S, Alexander EK, Guttler RB, Hershman JM, Babu V, Blevins TC, Moore P, Andruss B, Labourier E. (2014). Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. Thyroid 24: 1479-1487
36. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. (2012). Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 35: 107-115
37. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J. (2011). Myeloidderived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13: 591-599
38. Ohki S, Shibata M, Gonda K, Machida T, Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H, Takenoshita S. (2012). Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep 28: 453-458
39. Suzuki S, Shibata M, Gonda K, Kanke Y, Ashizawa M, Ujiie D, Suzushino S, Nakano K, Fukushima T, Sakurai K, Tomita R, Kumamoto K, Takenoshita S. (2013). Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer. Mol Clin Oncol 1: 959-964
40. Khaled YS, Ammori BJ, Elkord E. (2014). Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J Immunol Res 2014: 879897
41. Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H, Zhao K. (2013). Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 8: e57114
42. Huang A, Zhang B, Wang B, Zhang F, Fan KX, Guo YJ. (2013). Increased CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother 62: 1439-1451
43. Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, Abrams Z, Luedke E, Lesinski GB, Mundy-Bosse B, Bekaii-Saab T, CarsonWE 3rd. (2015). Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother 64: 149-159
44. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, Büttner P, Garbe C, Pawelec G. (2013). Myeloidderived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1-or melan-A-specific T cells. Clin Cancer Res 20: 1601-1609
45. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. (2011). Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60: 1419-1430